Deal facts
- Buyer
- Chiesi Farmaceutici S.p.A.
- Target
- KalVista Pharmaceuticals, Inc.
- Deal value
- Not disclosed
- Announced
- 29 April 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Chiesi Farmaceutici S.p.A. has agreed to acquire KalVista Pharmaceuticals, Inc. in a going private transaction structured as a cash consideration deal. The Italian healthcare company announced the agreement on 29 April 2026, with the target being a US-based biotechnology firm operating within the healthcare sector. The transaction was completed on 11 June 2026, marking the end of the public listing for the acquired entity. No specific deal value was reported in the available data.
The acquisition represents a strategic move by the buyer to integrate the target's assets into its existing portfolio. This deal concludes the period during which KalVista Pharmaceuticals operated as an independent public company. The transaction is now final following the completion date.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Chiesi Farmaceutici S.p.A. completes acquisition of KalVista Pharmaceuticals, Inc.
Introductory Note On April 29, 2026, we previously reported with the U.S. Securities and Exchange Commission (the “SEC”) that KalVista Pharmaceuticals, Inc., a Delaware corporation (“ us ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated April 29, 2026, with Chiesi Farmaceutici S.p.A., an Italian società per azioni (“ Parent ”), Skyline Merger Sub
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.
ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…
- Buyer
- ArcheNova Technology Co., Ltd
- Target
- ArcheNova Biotech Corp.
- Deal value
- USD 2,000,000,000
- Deal type
- going private
Onyx Bidco LLC to acquire Option Care Health, Inc.
Onyx Bidco LLC has agreed to acquire Option Care Health, Inc. in a cash transaction. The deal, announced on 5 October 2026, involves the US-based buyer purchasing the US…
- Buyer
- Onyx Bidco LLC
- Target
- Option Care Health, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Lifecore Inc. to acquire Lifecore Biomedical, Inc.
Lifecore Inc. has agreed to acquire Lifecore Biomedical, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 28 September 20…
- Buyer
- Lifecore Inc.
- Target
- Lifecore Biomedical, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
TULIP UK BIDCO LIMITED to acquire Spire Healthcare Group plc
TULIP UK BIDCO LIMITED has agreed to acquire Spire Healthcare Group plc in a going private transaction valued at approximately GBP 1.0265 billion. The deal structure inv…
- Buyer
- TULIP UK BIDCO LIMITED
- Target
- Spire Healthcare Group plc
- Deal value
- GBP 1,026,500,000
- Deal type
- going private
Curium US Holdings LLC to acquire Lantheus Holdings, Inc.
Curium US Holdings LLC has agreed to acquire Lantheus Holdings, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 3 August…
- Buyer
- Curium US Holdings LLC
- Target
- Lantheus Holdings, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Chiesi Farmaceutici S.p.A.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive